Regeneron Pharmaceuticals | REGN - Ordinary Share Capital


Regeneron Pharmaceuticals reported $105M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 35.32M 2.51M Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
Astellas Pharma JPY 1.79B 81K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Kyowa Hakko Kirin JPY 523.49M 1000 Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Novartis USD 1.91B 10.64M Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Teva Pharmaceutical Industries USD 1.16B 16.72M Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026